Strahlentherapie des Mediastinalen Hodgkin-Lymphoms

Literaturverzeichnis
Anselmo, A.P., Meloni, G., Cavalieri, E., Proia, A., Enrici, R.M., Funaro, D., Pescarmona, E., and Mandelli, F.
(2000). Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory
Hodgkin's disease patients. Ann Hematol 79, 79-82.
Armstrong, A.A., Alexander, F.E., Cartwright, R., Angus, B., Krajewski, A.S., Wright, D.H., Brown, I., Lee, F.,
Kane, E., and Jarrett, R.F. (1998). Epstein-Barr virus and Hodgkin's disease: further evidence for the three
disease hypothesis. Leukemia 12, 1272-1276.
Bakemeier, R.F., Anderson, J.R., Costello, W., Rosner, G., Horton, J., Glick, J.H., Hines, J.D., Berard, C.W.,
and DeVita, V.T., Jr. (1984). BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater
duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the
Eastern Cooperative Oncology Group study. Ann Intern Med 101, 447-456.
Ballova, V., Ruffer, J.U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H.K., Duhmke, E., Worst, P.,
Wilhelmy, M., Naumann, R., Hentrich, M., Eich, H.T., Josting, A., Loffler, M., Diehl, V., and Engert, A. (2005).
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients
with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann
Oncol 16, 124-131.
Bär, W., Alber, M., and Nüsslin, F. (2003a). [Fluence-modulated radiotherapy with an optimization-integrated
sequencer]. Z Med Phys 13, 12-15.
Bär, W., Schwarz, M., Alber, M., Bos, L.J., Mijnheer, B.J., Rasch, C., Schneider, C., Nüsslin, F., and Damen,
E.M. (2003b). A comparison of forward and inverse treatment planning for intensity-modulated radiotherapy of
head and neck cancer. Radiother Oncol 69, 251-258.
Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V., and
Engert, A. (2005). Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of
disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German
Hodgkin's Lymphoma Study Group. J Clin Oncol 23, 7555-7564.
Behringer, K., Josting, A., Schiller, P., Eich, H.T., Bredenfeld, H., Diehl, V., and Engert, A. (2004). Solid
tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group.
Ann Oncol 15, 1079-1085.
Biti, G., Cellai, E., Magrini, S.M., Papi, M.G., Ponticelli, P., and Boddi, V. (1994). Second solid tumors and
leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat
Oncol Biol Phys 29, 25-31.
Böll, B., Borchmann, P., and Engert, A. (2010a). Experimentelle Therapie des Hodgkin-Lymphoms. Der
Onkologe 16, 48-54.
Böll, B., Borchmann, P., Topp, M.S., Hanel, M., Reiners, K.S., Engert, A., and Naumann, R. (2010b).
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 148, 480-482.
Boll, B., Bredenfeld, H., Gorgen, H., Halbsguth, T., Eich, H.T., Soekler, M., Markova, J., Keller, U., Graeven,
U., Kremers, S., Geissler, M., Trenn, G., Fuchs, M., von Tresckow, B., Eichenauer, D.A., Borchmann, P., and
Engert, A. (2011). Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly
patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118, 6292-6298.
Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F., and Valagussa, P. (2004). ABVD plus
subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin
Oncol 22, 2835-2841.
Bonadonna, G., Valagussa, P., and Santoro, A. (1986). Alternating non-cross-resistant combination
chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 104, 739-746.
Borchmann, P., Engert, A., Pluetschow, A., Fuchs, M., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M.,
Villalobos, M., Zijlstra, J., Soekler, M., Stein, H., Eich, H.T., Mueller, R.P., and Diehl, V. (2008). Dose-
Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of
ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with
Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)
HD14 Trial. ASH Annual Meeting Abstracts 112, 367.
Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A.D., Eich, H.T., Mueller-Hermelink,
H.K., Kanz, L., Greil, R., Rank, A., Paulus, U., Smardova, L., Huber, C., Dorken, B., Nerl, C., Krause, S.W.,
Mueller, R.P., Fuchs, M., and Engert, A. (2011). Eight cycles of escalated-dose BEACOPP compared with four
cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without
radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the
German Hodgkin Study Group. J Clin Oncol 29, 4234-4242.
122